Price
$27.12-21.71%Social Signal Score
Analyst Ratings
12 analystsRevenue
$123.79M+174.91%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James Patrick Mackin
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 1,800
- Beta
- 1.28
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 1.63
Financials
Revenue
$123.79M+174.9%Net Income
$-7.93M-373.6%EBITDA
$9.94M+48.8%Free Cash Flow
$-17.57M-845.1%EPS (diluted)
$-0.16-277.8%Shares Outstanding (diluted)
48.72M+45.7%Operating Expenses
$73.03MCash & Debt
$48.40MReturn of Capital
$0.00Revenue by Segment (annual)
$441.33MDividend per Share
$0.03Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $441.33M | $9.77M | $0.22 |
| 2024 | $388.54M | $-13.36M | $-0.32 |
| 2023 | $354.00M | $-30.69M | $-0.75 |
| 2022 | $313.79M | $-19.19M | $-0.48 |
| 2021 | $298.84M | $-14.83M | $-0.38 |
| 2020 | $253.23M | $-16.68M | $-0.44 |
| 2019 | $276.22M | $1.72M | $0.05 |
| 2018 | $262.84M | $-3.81M | $-0.11 |
| 2017 | $189.70M | $3.70M | $0.11 |
| 2016 | $180.38M | $10.78M | $0.33 |
| 2015 | $145.90M | $4.00M | $0.14 |
| 2014 | $144.64M | $7.32M | $0.26 |
| 2013 | $140.76M | $16.17M | $0.59 |
| 2012 | $131.72M | $7.95M | $0.29 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from AORT's reported EPS growth of -2.1% a year over 13 years.
- EPS in 5 years
- $0.19
- Implied price
- $3.49
- Return from $18.53
- -28.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.73 — -90.6% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -12.1% | -40.7% | -38.0% | -35.7% | -33.7% | -31.9% |
| -7.1% | -37.3% | -34.5% | -32.1% | -29.9% | -28.0% |
| -2.1% | -34.0% | -31.0% | -28.4% | -26.2% | -24.2% |
| 2.9% | -30.6% | -27.4% | -24.7% | -22.4% | -20.3% |
| 7.9% | -27.2% | -23.9% | -21.1% | -18.6% | -16.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (6)
- Newsmarketbeat.com·16d ago·Negative
Artivion Q3 Earnings Call Highlights Artivion NYSE: AORT reported 9% constant-currency revenue growth in the third quarter of 2026, while adjusted earnings declined as the medical device maker invested in manufacturing and prepared for the U.S. launch of its NEXUS aortic repair system.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript Artivion, Inc. (AORT) Q3 2026 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Negative
Artivion (AORT) Lags Q3 Earnings Estimates Artivion (AORT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
View source ↗ - Newsprnewswire.com·17d ago·Negative
…d 8% to $22.5 million in the third quarter of 2026 compared to $24.6 million in the third quarter of 2025 ATLANTA, Nov. 5, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2026. "In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth throu…
View source ↗ - Newsprnewswire.com·31d ago·Neutral
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2026 Financial Results ATLANTA, Oct. 22, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2026 financial results will be released on Thursday, November 5, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
View source ↗ - Newsmarketbeat.com·107d ago·Neutral
Artivion Q2 Earnings Call Highlights Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $-0.04 per share
Typical surprise -56.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$0.08 vs $-0.06beat
- Thu, Aug 6$-0.28 vs $0.00miss
- Thu, May 7$0.03 vs $0.06miss
- Thu, Feb 12$0.05 vs $0.14miss
- Thu, Nov 6$0.16 vs $0.14beat
- Thu, Aug 7$0.03 vs $0.11miss
Estimates and results for AORT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AORT officers and directors.
- Bought
- —
- Sold
- $15.1m
0 trades
48 trades
- Green Andrew Msold
- Green Andrew Msold
- Green Andrew Msold
- Mackin James Psold
- Green Andrew Msold
- Berry Lance Asold
- Holloway Jean Fsold
- Green Andrew Msold
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Sep 11, 2026 (22d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Sep 7, 2026 (53d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Nov 18, 2025 (40d later)Sell$1,001 - $15,000
- Tina Smithsenate · MN · disclosed Nov 20, 2023 (10d later)Buy$50,001 - $100,000
- Tina Smithsenate · MN · disclosed Nov 20, 2023 (4d later)Buy$50,001 - $100,000
- Josh Gottheimerhouse · NJ05 · disclosed Aug 21, 2023 (38d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jul 11, 2023 (28d later)Sell$1,001 - $15,000
- Tina Smithsenate · MN · disclosed Oct 17, 2022 (24d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
